Business
Citi Pharma : Transmission of financial statements for the Nine Months period ended 31 March 2025
Citi Pharma : Transmission of financial statements for the Nine Months period ended 31 March
About this update from Citi Pharma Ltd.
[{"type":"text","content":"\n \n CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2025\n \n CITI PHARMA\n \n \n Email: [email protected] Website: https://www.citipharma.com.pk\n Tel: 042 - 35316587\n \n \n Address: 588-Q, Johar Town Lahore\n \n TABLE OF CONTENTS\n \n \n Company Information\n \n \n Company Information 3\n \n \n Director's Report 4\n \n \n Financial Statements 8\n \n \n DIRECTORS' REPORT\n \n \n \n We are pleased to present the unaudited condensed interim financial statements of the Company for the half year ended March 31, 2025. These financial statements have been prepared in accordance with the requirements of the International Accounting Standard (IAS) 34 'Interim Financial Reporting' and the director report is prepared in accordance with section 227 of Companies Act, 2017 and Chapter XII of the Listed Companies (Code of Corporate Governance) Regulations, 2019.\n \n \n \n COMPOSITION OF BOARD\n \n \n The total number of directors are 7 as the following:\n \n \n Male 5\n \n \n Female 2\n \n Sr.\n \n \n No.\n \n \n Category\n \n \n Name\n \n \n 1\n \n \n Independent Director\n \n \n Mr. Abdul Jaleel Shaikh\n \n \n Ms. Farzin Khan\n \n \n 2\n \n \n Executive Director\n \n \n Mr. Rizwan Ahmad\n \n \n Mr. Dr. Zameer Ul Hassan Shah\n \n \n \n 3\n \n \n \n Non-Executive Director\n \n \n Mr. Nadeem Amjad\n \n \n Mr. Muhammad Naeem\n \n \n Ms. Saira Aslam\n \n FINANCIAL HIGHLIGHTS\n \n \n Despite a challenging macroeconomic environment and inflationary pressures, the Company has demonstrated operational resilience and maintained steady growth in key financial indicators. Net Sales for the nine months period stood at PKR 10.1 billion, reflecting an increase of 6.32% as compared to PKR 9.5 billion reported during the corresponding period of the previous year. Gross Profit (GP) increased to PKR 1,456 million, compared to PKR 1,343 million in the same period last year, marking an improvement of 8.41%. The gross profit margin has shown stability due to effective cost control measures, better procurement strategies and operational efficiencies. Earnings Per Share (EPS) for the period under review, stood at PKR 2.97 which is marginally lower than PKR 2.98 recorded in the same period last year. This slight decrease is due to one-off Selling and distribution costs incurred to support future expansion of the commercial department...